Screener
BridgeBio Pharma BBIO Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Treasury stock, at cost; 8,678,997 shares as of March 31, 2026; 7,597,172 shares as of December 31, 2025 | (405,776) | (323,276) |
| Additional paid-in capital | 2,112,454 | 2,057,646 |
| Accumulated other comprehensive income (loss) | (8) | 12 |
| Accumulated deficit | (3,985,237) | (3,821,194) |
| Total BridgeBio stockholders’ deficit | (2,278,363) | (2,086,610) |
| Noncontrolling interests | 10,439 | 10,599 |
| Total stockholders’ deficit | (2,267,924) | (2,076,011) |
| Total liabilities, redeemable convertible noncontrolling interests and stockholders’ deficit | $1,370,981 | $936,025 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's retained earnings?
- BridgeBio Pharma (BBIO) reported retained earnings of -$3.99B in Q1 2026.
- How has BridgeBio Pharma's retained earnings changed year-over-year?
- BridgeBio Pharma's retained earnings decreased by 22.1% year-over-year, from -$3.26B to -$3.99B.
- What is the long-term trend for BridgeBio Pharma's retained earnings?
- Over 5 years (2020 to 2025), BridgeBio Pharma's retained earnings has grown at a 33.9% compound annual growth rate (CAGR), from -$888.76M to -$3.82B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about BridgeBio Pharma's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude